论文部分内容阅读
各种恶性肿瘤的生物学行为有很大差异,现有的形态学方法并不能满意地区分同一类肿瘤中预后不同的患者。近年恶性肿瘤细胞增生动力学及某些生物标记物引起了肿瘤学者的兴趣。有人试图据此来区分具有相同形态的肿瘤中可能存在的亚群。本文对28例中、晚期直肠腺癌测定了氚化胸腺嘧啶核苷标记率(LI)。探讨了它们和肿瘤其它临床、病理特征之间可能的关系。旨在通过 LI 测定有助于寻找一种可以区分不同预后
The biological behaviors of various malignant tumors are very different, and the existing morphological methods are not satisfactory for distinguishing patients with different prognosis in the same type of tumors. In recent years, the kinetics of malignant cell proliferation and certain biomarkers have attracted the interest of oncologists. Some people try to distinguish the possible subpopulations of tumors with the same morphology. In this paper, the labeling rate of tritiated thymidine (LI) was determined in 28 cases of advanced adenocarcinoma of the rectum. The possible relationship between them and other clinical and pathological features of the tumor was explored. Designed to help find a way to distinguish different prognoses by measuring LI